Procalcitonin-guided protocol is not useful to manage antibiotic therapy in febrile neutropenia: a randomized controlled trial

Annals of Hematology

Volumn 95, Issue 7, 2016, Pages 1169-1176

  Lima, Stella Sala Soares ^a,b   Nobre, Vandack ^a   de Castro Romanelli, Roberta Maia ^a   Clemente, Wanessa Trindade ^a   da Silva Bittencourt, Henrique Neves ^c   Melo, Ana Catarina Mourão ^a   Salomão, Luciana Caetano Botelho ^a   Serufo, José Carlos ^a  

^a FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

^b Radiotherapy Department of Instituto Mario Penna   (Brazil)

^c UNIVERSITY OF MONTREAL   (Canada)

Author keywords

Antibiotic; Febrile neutropenia; Infection; Procalcitonin; Treatment

Indexed keywords

AMINOGLYCOSIDE; CARBAPENEM; CEFEPIME; CEFTAZIDIME; PIPERACILLIN PLUS TAZOBACTAM; PROCALCITONIN; ANTIINFECTIVE AGENT; BIOLOGICAL MARKER; CALCITONIN;

ADULT; ALGORITHM; ANTIBIOTIC THERAPY; ARTICLE; BACTEREMIA; BACTERIAL SUPERINFECTION; CLINICAL PROTOCOL; CONTROLLED STUDY; DISEASE DURATION; DRUG EXPOSURE; DRUG USE; FEBRILE NEUTROPENIA; FEMALE; FEVER; HOSPITALIZATION; HUMAN; INFECTION RATE; MAJOR CLINICAL STUDY; MALE; MANAGED CARE; MORTALITY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; RELAPSE; SENSITIVITY AND SPECIFICITY; TREATMENT DURATION; TREATMENT INDICATION; BLOOD; DISEASE MANAGEMENT; FOLLOW UP; LENGTH OF STAY; MIDDLE AGED; TRENDS;

ADULT; ANTI-BACTERIAL AGENTS; BIOMARKERS; CALCITONIN; DISEASE MANAGEMENT; FEBRILE NEUTROPENIA; FEMALE; FOLLOW-UP STUDIES; HUMANS; LENGTH OF STAY; MALE; MIDDLE AGED;

EID: 84964515113     PISSN: 09395555     EISSN: 14320584     Source Type: Journal    
DOI: 10.1007/s00277-016-2639-5     Document Type: Article

References (30)

1. Sakr Y, Sponholz C, Tuche F, Brunkhorst F, Reinhart K (2008) The role of procalcitonin in febrile neutropenic patients: review of the literature. Infection 36:396–407
2. Bodey GP (2009) The changing face of febrile neutropenia-from monotherapy to moulds to mucositis. Fever and neutropenia: the early years. J Antimicrob Chemother 63(Suppl 1):i3–13
3. Klastersky J, Awada A, Paesmans M, Aoun M (2011) Febrile neutropenia: a critical review of the initial management. Crit Rev Oncol Hematol 78:185–194
4. Cornillon J, Bouteloup M, Lambert C (2011) Evaluation of procalcitonin and CRP as sepsis markers in 74 consecutive patients admitted with prolonged febrile neutropenia. J Infect 63:93–95
5. Freifeld AG, Bow EJ, Sepkowitz KA et al (2011) Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of america. Clin Infect Dis 52:e56–e93
6. Penack O, Buchheidt D, Christopeit M et al (2011) Management of sepsis in neutropenic patients: guidelines from the infectious diseases working party of the German Society of Hematology and Oncology. Ann Oncol 22:1019–1029
7. Tamura K (2005) Clinical guidelines for the management of neutropenic patients with unexplained fever in Japan: validation by the Japan Febrile Neutropenia Study Group. Int J Antimicrob Agents 26(Suppl 2):S123–7, discussion S133-40
8. Gea-Banacloche J (2011) Biomarkers in fever and neutropenia: a solution in search of a problem? Crit Care Med 39:1205–1206
9. Schuetz P, Briel M, Christ-Crain M et al (2012) Procalcitonin to guide initiation and duration of antibiotic treatment in acute respiratory infections: an individual patient data meta-analysis. Clin Infect Dis 55:651–662
10. Agarwal R, Schwartz DN (2011) Procalcitonin to guide duration of antimicrobial therapy in intensive care units: a systematic review. Clin Infect Dis 53:379–387
11. Engel A, Steinbach G, Kern P, Kern WV (1999) Diagnostic value of procalcitonin serum levels in neutropenic patients with fever: comparison with interleukin-8. Scand J Infect Dis 31:185–189
12. Gac AC, Parienti JJ, Chantepie S et al (2011) Dynamics of procalcitonin and bacteremia in neutropenic adults with acute myeloid leukemia. Leuk Res 35:1294–1296
13. Hambach L, Eder M, Dammann E et al (2002) Diagnostic value of procalcitonin serum levels in comparison with C-reactive protein in allogeneic stem cell transplantation. Haematologica 87:643–651
14. Jimeno A, García-Velasco A, del Val O et al (2004) Assessment of procalcitonin as a diagnostic and prognostic marker in patients with solid tumors and febrile neutropenia. Cancer 100:2462–2469
15. Kitanovski L, Jazbec J, Hojker S, Gubina M, Derganc M (2006) Diagnostic accuracy of procalcitonin and interleukin-6 values for predicting bacteremia and clinical sepsis in febrile neutropenic children with cancer. Eur J Clin Microbiol Infect Dis 25:413–415
16. Koivula I, Juutilainen A (2011) Procalcitonin is a useful marker of infection in neutropenia. Leuk Res 35:1288–1289
17. Persson L, Engervall P, Magnuson A et al (2004) Use of inflammatory markers for early detection of bacteraemia in patients with febrile neutropenia. Scand J Infect Dis 36:365–371
18. Robinson JO, Lamoth F, Bally F, Knaup M, Calandra T, Marchetti O (2011) Monitoring procalcitonin in febrile neutropenia: what is its utility for initial diagnosis of infection and reassessment in persistent fever? PLoS One 6:e18886
19. Ruokonen E, Nousiainen T, Pulkki K, Takala J (1999) Procalcitonin concentrations in patients with neutropenic fever. Eur J Clin Microbiol Infect Dis 18:283–285
20. Secmeer G, Devrim I, Kara A et al (2007) Role of procalcitonin and CRP in differentiating a stable from a deteriorating clinical course in pediatric febrile neutropenia. J Pediatr Hematol Oncol 29:107–111
21. von Lilienfeld-Toal M, Dietrich MP, Glasmacher A et al (2004) Markers of bacteremia in febrile neutropenic patients with hematological malignancies: procalcitonin and IL-6 are more reliable than C-reactive protein. Eur J Clin Microbiol Infect Dis 23:539–544
22. Giamarellos-Bourboulis EJ, Grecka P, Poulakou G, Anargyrou K, Katsilambros N, Giamarellou H (2001) Assessment of procalcitonin as a diagnostic marker of underlying infection in patients with febrile neutropenia. Clin Infect Dis 32:1718–1725
23. Giamarellou H, Giamarellos-Bourboulis EJ, Repoussis P et al (2004) Potential use of procalcitonin as a diagnostic criterion in febrile neutropenia: experience from a multicentre study. Clin Microbiol Infect 10:628–633
24. De Pauw B, Walsh TJ, Donnelly JP et al (2008) Revised definitions of invasive fungal disease from the European organization for research and treatment of cancer/invasive fungal infections cooperative group and the national institute of allergy and infectious diseases mycoses study group (EORTC/MSG) consensus group. Clin Infect Dis 46:1813–1821
25. National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE), version 4.0. Available at: http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_QuickReference_8.5x11.pdf. Accessed 12 Mar 2013
26. Klastersky J, Paesmans M, Rubenstein EB et al (2000) The multinational association for supportive care in cancer risk index: a multinational scoring system for identifying low-risk febrile neutropenic cancer patients. J Clin Oncol 18:3038–3051
27. Pizzo PA, Armstrong D, Bodey G et al (1990) From the immunocompromised host society: the design, analysis, and reporting of clinical trials on the empirical antibiotic management of the neutropenic patient. J Infect Dis 161:397–401
28. Nobre V, Harbarth S, Graf JD, Rohner P, Pugin J (2008) Use of procalcitonin to shorten antibiotic treatment duration in septic patients: a randomized trial. Am J Respir Crit Care Med 177:498–505
29. Robinson JO, Calandra T, Marchetti O (2005) Utility of procalcitonin for the diagnosis and the follow-up of infections in febrile neutropenic patients. Rev Med Suisse 1:878–886
30. Schuetz P, Albrich W, Mueller B (2011) Procalcitonin for diagnosis of infection and guide to antibiotic decisions: past, present and future. BMC Med 9:107